Navigation Links
InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
Date:2/2/2012

BRISBANE, Calif., Feb. 2, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its fourth quarter and full year 2011 financial results at the close of the U.S. markets on Thursday, February 9, 2012.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

Interested investors and others may participate in the conference call by dialing 800-891-8257 (U.S.) or +1-212-271-4651 (international), conference ID# 21576715.  A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call.

To access the live webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140 (international), and entering the conference ID# 21576715.  

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2019)... ... August 22, 2019 , ... The EnozoPro® converts ordinary tap water ... germs and pathogens on hard surfaces including E. Coli, Salmonella, MRSA, Listeria and Legionella. ... For more information, visit the product page at rovingblue.com , ”At Enozo, our mission ...
(Date:8/14/2019)... ... August 13, 2019 , ... Chata ... mobile phases for QC laboratories. After gaining a few significant clients, Lifecycle purchased ... into a valued supplier of manufacturing processing solutions, including reagents for tissue processing. ...
(Date:8/6/2019)... ... August 06, 2019 , ... Shoreline Biome, a ... strain level, has announced partnerships with six international distributors. , The distributors ... organizations in Australia, Benelux, Indonesia, Korea, Malaysia, Myanmar, New Zealand, Singapore, the United ...
(Date:7/30/2019)... ... July 30, 2019 , ... The summer season ... events company. Not only has the company already hosted many of its signature ... Parties to its guests. , With Lajollacooks4u’s Private Cooking Parties, guests prepare and ...
Breaking Biology Technology:
(Date:8/1/2019)... Fla. (PRWEB) , ... August 01, 2019 , ... The ... the point of care. It is fully developed with over 100 units deployed ... applications into new fields of use, our collaboration with axiVEND will give us a ...
(Date:8/1/2019)... ... July 31, 2019 , ... ... Check your local listings for more information. , Factor Bioscience Inc. (Factor) is ... and genetic and age-related diseases. This segment of Advancements will explore how Factor ...
(Date:7/24/2019)... ... July 24, 2019 , ... NDA Partners Chairman Carl ... with more than 20 years of experience working in scientific research and FDA-regulated ... as an Expert Consultant. , Dr. Hartzfeld has experience in all aspects of ...
Breaking Biology News(10 mins):